NOVELSTEM Stock OTC Markets

NSTM

US4362331005

Biotechnology & Medical Research

Delayed OTC Markets 17:59:07 05/10/2021 +03			5-day change	1st Jan Change
0.2700 ^USD	+7.57%		-3.50%	+44.75%

08-14	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

NovelStem International Corp. is a development stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patientsâ€™ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	386K 348K 321K 290K 550K 36.19M 563K 3.85M 1.53M 19.38M 1.45M 1.42M 61.68M	P/E 2024	-0.11x	P/E 2025	0.18x
Enterprise Value	2.29M 2.06M 1.91M 1.72M 3.26M 215M 3.34M 22.85M 9.11M 115M 8.59M 8.41M 366M	EV / Sales 2024	398,132,333x	EV / Sales 2025	-
Free-Float	38.73%	Yield 2024 *	-	Yield 2025	-

08-14	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-26	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	NovelStem International Corp. Auditor Raises 'Going Concern' Doubt	CI
11-12	NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
07/08/25	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
20/05/25	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
08/04/25	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
07/04/25	NovelStem International Corp. Auditor Raises 'Going Concern' Doubt	CI
15/11/24	NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
15/08/24	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
15/05/24	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
01/04/24	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

20/05/25	NovelStem Announces Material Developments and Strategic Repositioning of the Company	AQ
31/03/23	NOVELSTEM INTERNATIONAL CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
17/01/23	NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
14/11/22	NOVELSTEM INTERNATIONAL CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
04/10/22	NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers (form 8-K)	AQ

Manager	Title	Age	Since
Christine Jenkins DFI	Director of Finance/CFO	63	29/09/2022
Jan Loeb PSD	President	67	13/01/2023

Director	Title	Age	Since
Mitchell Rubenstein CHM	Chairman	72	22/01/1993
Jan Loeb CHM	Chairman	67	01/07/2018
Eric Richman BRD	Director/Board Member	65	01/06/2018

NOVELSTEM Stock OTC Markets

Stocks

NSTM

US4362331005

Biotechnology & Medical Research

Valuation: NOVELSTEM

Latest news: NOVELSTEM

Press Releases: NOVELSTEM

Quotes and Performance

Managers and Directors: NOVELSTEM

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NOVELSTEM	+7.57%	-3.50%	-	-	386K
WUXI APPTEC CO., LTD.	+1.10%	+1.03%	+62.53%	+70.47%	67.53B
ARGENX SE	+0.89%	+8.29%	+13.52%	+91.96%	60.74B
LONZA GROUP AG	+0.33%	-0.80%	+20.27%	+98.75%	55.66B
BEONE MEDICINES AG	-0.06%	+8.71%	+11.52%	+111.70%	47.97B
IQVIA HOLDINGS INC.	-1.60%	+1.65%	+21.90%	+39.03%	45.24B
REVOLUTION MEDICINES, INC.	-2.05%	-0.57%	+168.33%	+798.93%	39.08B
CELLTRION, INC.	+1.21%	+4.75%	+27.30%	+52.81%	35.34B
GENMAB A/S	-0.87%	-2.56%	+80.21%	+56.86%	33.45B
INSMED INCORPORATED	-2.27%	+8.94%	-39.05%	+395.73%	26.49B
Average	+0.43%	+2.70%	+40.73%	+190.69%	46B
Weighted average by Cap.	-0.13%	+2.88%	+41.09%	+166.32%

	2024	2025
Net sales	0.01 0.01 0.01 0.01 0.02 1.13 0.02 0.12 0.05 0.6 0.05 0.04 1.92	-
Net income	-3.23M -2.91M -2.69M -2.43M -4.6M -303M -4.72M -32.26M -12.86M -162M -12.13M -11.88M -517M	2.38M 2.14M 1.98M 1.79M 3.39M 223M 3.47M 23.75M 9.47M 120M 8.93M 8.74M 380M
Net Debt	4.41M 3.98M 3.67M 3.32M 6.28M 414M 6.44M 44.03M 17.55M 222M 16.56M 16.21M 705M	1.9M 1.72M 1.59M 1.43M 2.71M 179M 2.78M 19M 7.57M 95.61M 7.14M 6.99M 304M